Progyny, Inc. Common Stock

Progyny trades at a P/E of 25.3 while sitting 62.5 on the RSI—elevated but not yet overbought—suggesting the market is pricing in meaningful growth expectations. With a $1.5B market cap and short interest at 9.9%, there's meaningful skepticism embedded in positioning, though not extreme squeeze risk. The stock trades below its 52-week high, indicating recent pullback despite valuation premium to typical healthcare services comps. The combination of elevated multiples paired with moderate short positioning and distance from yearly peaks suggests a name caught between growth narrative believers and value-conscious skeptics, making it vulnerable to sentiment shifts on earnings execution.